FREEDOMM: Fifth-line or Later Real-world Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-free Interval and Overall Survival in the US

Figshare 2026 Open access

Read full text
Authors: Adis Journals on behalf of:, Sikander Ailawadhi, Doris K. Hansen, Binod Dhakal, Leyla Osman Shune, Larry D. Anderson, Kevin DeBraganca, Tamar Lengil, Victoria R. Alegria, Matthew Perciavalle, Jack Hoang Lu, Elizabeth Sacchi
+6 more Seina Lee, Bruno Emond, Stephen Huo, Todd Bixby, Zaina P. Qureshi, Douglas W. Sborov
DOI: 10.6084/m9.figshare.31424816
Cited by: 0

Abstract

Article full text The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).© The authors, CC-BY-NC [2026].

Fields of Study & Subjects

CAR-T cell therapy research Multiple Myeloma Research and Treatments Multiple Sclerosis Research Studies

Publication details

Journal / source
Figshare
Publication date
12 March 2026
Language
EN